The DiSCOVER Trial
Decentralized Study of Celiprolol on vEDS-related Event Reduction
Acer Therapeutics plans to conduct a clinical trial in the U.S. to evaluate the efficacy of a medicine known as celiprolol for the treatment of vascular Ehlers-Danlos Syndrome (vEDS). The study is being planned to evaluate males and females who have a confirmed diagnosis of vEDS by a COL3A1 mutation verified by genetic testing.
As planning for the trial progresses, we are actively looking for potential participants with a confirmed diagnosis of vEDS who are interested in participating in this investigational trial. As with any clinical study, participation will be subject to a number of inclusion and exclusion criteria.
Celiprolol is an investigational product and the safety and efficacy has not been established. There is no guarantee that celiprolol will receive health authority approval or become commercially available for vEDS.
vEDS as confirmed with a
positive COL3A1 mutation